AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...
AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver ...
AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...
Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 ...
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...
AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He ...
GlobalData on MSN
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
The approval relies on positive data from the POTOMAC Phase III trial.
AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on ...
Follow the latest headlines from ABC News, Australia's most trusted media source, with live events, audio and on-demand video ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results